Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors

Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the first-line treatment of ALK-positive metastatic non-small cell lung cancer, frequently associated with psychiatric adverse events. Method: This study presents the clinical case of a patient who was successfully treated with low-dose trazodone for lorlatinib-induced psychiatric symptoms. In addition, an overview of the existing literature on the management of psychiatric adverse events (AEs) associated with ALK inhibitors is provided. Results and conclusions: Based on the evidence presented and the preliminary outcomes observed in the reported case, this study aims to outline a management strategy for lorlatinib-related psychiatric complications.